vs
Avantor, Inc.（AVTR）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是Avantor, Inc.的1.3倍（$2.1B vs $1.7B），Roper Technologies净利率更高（15.8% vs 3.1%，领先12.6%），Roper Technologies同比增速更快（11.3% vs -1.4%），Roper Technologies自由现金流更多（$507.0M vs $117.2M），过去两年Roper Technologies的营收复合增速更高（10.5% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
AVTR vs ROP — 直观对比
营收规模更大
ROP
是对方的1.3倍
$1.7B
营收增速更快
ROP
高出12.7%
-1.4%
净利率更高
ROP
高出12.6%
3.1%
自由现金流更多
ROP
多$389.8M
$117.2M
两年增速更快
ROP
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $2.1B |
| 净利润 | $52.4M | $331.0M |
| 毛利率 | 31.5% | 69.4% |
| 营业利润率 | 7.6% | 27.2% |
| 净利率 | 3.1% | 15.8% |
| 营收同比 | -1.4% | 11.3% |
| 净利润同比 | -89.5% | 53.7% |
| 每股收益（稀释后） | $0.08 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.7B | $2.1B | ||
| Q3 25 | $1.6B | $2.0B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.7B | $1.9B | ||
| Q3 24 | $1.7B | $1.8B | ||
| Q2 24 | $1.7B | $1.7B |
净利润AVTRROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $52.4M | $428.4M | ||
| Q3 25 | $-711.8M | $398.5M | ||
| Q2 25 | $64.7M | $378.3M | ||
| Q1 25 | $64.5M | $331.1M | ||
| Q4 24 | $500.4M | $462.3M | ||
| Q3 24 | $57.8M | $367.9M | ||
| Q2 24 | $92.9M | $337.1M |
毛利率AVTRROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 31.5% | 69.5% | ||
| Q3 25 | 32.4% | 69.5% | ||
| Q2 25 | 32.9% | 69.2% | ||
| Q1 25 | 33.8% | 68.7% | ||
| Q4 24 | 33.4% | 68.3% | ||
| Q3 24 | 32.9% | 69.2% | ||
| Q2 24 | 34.1% | 69.5% |
营业利润率AVTRROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 7.6% | 28.6% | ||
| Q3 25 | -40.0% | 28.4% | ||
| Q2 25 | 7.7% | 28.2% | ||
| Q1 25 | 9.3% | 27.9% | ||
| Q4 24 | 37.8% | 28.0% | ||
| Q3 24 | 7.3% | 28.1% | ||
| Q2 24 | 10.3% | 28.8% |
净利率AVTRROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 3.1% | 20.8% | ||
| Q3 25 | -43.8% | 19.8% | ||
| Q2 25 | 3.8% | 19.5% | ||
| Q1 25 | 4.1% | 17.6% | ||
| Q4 24 | 29.7% | 24.6% | ||
| Q3 24 | 3.4% | 20.8% | ||
| Q2 24 | 5.5% | 19.6% |
每股收益（稀释后）AVTRROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.08 | $3.97 | ||
| Q3 25 | $-1.04 | $3.68 | ||
| Q2 25 | $0.09 | $3.49 | ||
| Q1 25 | $0.09 | $3.06 | ||
| Q4 24 | $0.73 | $4.29 | ||
| Q3 24 | $0.08 | $3.40 | ||
| Q2 24 | $0.14 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $382.9M |
| 总债务越低越好 | $3.9B | $9.7B |
| 股东权益账面价值 | $5.6B | $18.8B |
| 总资产 | $11.8B | $34.6B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资AVTRROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $365.4M | $297.4M | ||
| Q3 25 | $251.9M | $320.0M | ||
| Q2 25 | $449.4M | $242.4M | ||
| Q1 25 | $315.7M | $372.8M | ||
| Q4 24 | $261.9M | $188.2M | ||
| Q3 24 | $285.3M | $269.6M | ||
| Q2 24 | $272.6M | $251.5M |
总债务AVTRROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $3.9B | $9.3B | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | $7.6B | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — |
股东权益AVTRROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $5.6B | $19.9B | ||
| Q3 25 | $5.6B | $20.0B | ||
| Q2 25 | $6.3B | $19.6B | ||
| Q1 25 | $6.1B | $19.2B | ||
| Q4 24 | $6.0B | $18.9B | ||
| Q3 24 | $5.6B | $18.5B | ||
| Q2 24 | $5.4B | $18.1B |
总资产AVTRROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $11.8B | $34.6B | ||
| Q3 25 | $11.7B | $34.6B | ||
| Q2 25 | $12.8B | $33.2B | ||
| Q1 25 | $12.3B | $31.4B | ||
| Q4 24 | $12.1B | $31.3B | ||
| Q3 24 | $12.8B | $31.6B | ||
| Q2 24 | $12.7B | $29.8B |
负债/权益比AVTRROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.71× | 0.47× | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | 0.40× | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | — |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $507.0M |
| 自由现金流率自由现金流/营收 | 7.0% | 24.2% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRROP
| Q1 26 | — | — | ||
| Q4 25 | $152.7M | $738.0M | ||
| Q3 25 | $207.4M | $869.5M | ||
| Q2 25 | $154.4M | $404.1M | ||
| Q1 25 | $109.3M | $528.7M | ||
| Q4 24 | $173.3M | $722.2M | ||
| Q3 24 | $244.8M | $755.4M | ||
| Q2 24 | $281.1M | $384.1M |
自由现金流AVTRROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — |
自由现金流率AVTRROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — |
资本支出强度AVTRROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — |
现金转化率AVTRROP
| Q1 26 | — | — | ||
| Q4 25 | 2.91× | 1.72× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | 2.39× | 1.07× | ||
| Q1 25 | 1.69× | 1.60× | ||
| Q4 24 | 0.35× | 1.56× | ||
| Q3 24 | 4.24× | 2.05× | ||
| Q2 24 | 3.03× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
ROP
暂无分部数据
